Teva gets favorable Copaxone patent ruling in Netherlands
The District Court of the Hague (Netherlands) has issued a favorable ruling for Israel-headquartered Teva Pharmaceutical Industries (NYSE: TEVA) in a patent revocation action brought by US generic drugmaker Mylan (Nasdaq: MYL) seeking a court judgment that Teva’s European Patent (NL) 762,888 expiring May 2015 for its relapsing-remitting multiple sclerosis (RRMS) product Copaxone (glatiramer acetate injection) is invalid.
The District Court of the Hague rejected each one of the grounds of invalidity Mylan had raised against the claims of Teva’s ‘888 patent. The favorable ruling follows a similar outcome in the UK Court of Appeal in July 2013 which also affirmed that the claims of Teva’s patent are valid. Copaxone is a major product for Teva, generating second-quarter 2013 sales of $1.1 billion.
Full health regulator authorization would be needed for any copy version
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze